TN2015000249A1 - Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms - Google Patents

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Info

Publication number: TN2015000249A1
Authority: TN; Tunisia
Prior art keywords: myeloproliferative; telomerase inhibitors; treatment; myeloproliferative disorders; disorders
Prior art date: 2012-12-07

Application number

TNP2015000249A

Other languages

English (en)

Inventor

Monic J Stuart

Stephen Kelsey

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-07

Filing date

2015-06-05

Publication date

2016-10-03

2015-06-05 Application filed by Geron Corp filed Critical Geron Corp

2016-10-03 Publication of TN2015000249A1 publication Critical patent/TN2015000249A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Diabetes (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

TNP2015000249A 2012-12-07 2015-06-05 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms TN2015000249A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261734941P	2012-12-07	2012-12-07
US201361799069P	2013-03-15	2013-03-15
US201361900347P	2013-11-05	2013-11-05
PCT/US2013/070437 WO2014088785A1 (fr)	2012-12-07	2013-11-15	Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Publications (1)

Publication Number	Publication Date
TN2015000249A1 true TN2015000249A1 (en)	2016-10-03

Family

ID=50883867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000249A TN2015000249A1 (en)	2012-12-07	2015-06-05	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Country Status (37)

Country	Link
EP (3)	EP2928477B1 (fr)
JP (6)	JP6433911B2 (fr)
KR (4)	KR102662590B1 (fr)
CN (2)	CN111617252A (fr)
AP (1)	AP2015008504A0 (fr)
AU (4)	AU2013356533B2 (fr)
BR (1)	BR112015013260A2 (fr)
CA (2)	CA3188494A1 (fr)
CL (2)	CL2015001530A1 (fr)
CY (2)	CY1122169T1 (fr)
DK (3)	DK2928477T3 (fr)
EA (1)	EA032973B1 (fr)
ES (3)	ES2744790T3 (fr)
FI (2)	FI3646876T3 (fr)
FR (1)	FR25C1016I1 (fr)
HK (1)	HK1210940A1 (fr)
HR (3)	HRP20240624T1 (fr)
HU (4)	HUE049858T2 (fr)
IL (3)	IL280144B2 (fr)
LT (4)	LT3646876T (fr)
MA (2)	MA45504B1 (fr)
ME (1)	ME03538B (fr)
MX (3)	MX372753B (fr)
MY (2)	MY180634A (fr)
NL (1)	NL301326I2 (fr)
NZ (1)	NZ708920A (fr)
PH (2)	PH12019501008A1 (fr)
PL (3)	PL3646876T3 (fr)
PT (3)	PT2928477T (fr)
RS (2)	RS59363B1 (fr)
SG (3)	SG11201504383TA (fr)
SI (3)	SI3646876T1 (fr)
SM (2)	SMT202000328T1 (fr)
TN (1)	TN2015000249A1 (fr)
UA (3)	UA126015C2 (fr)
WO (1)	WO2014088785A1 (fr)
ZA (3)	ZA201504124B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1778711T3 (en)	2004-07-02	2017-10-02	Geron Corp	SYNTHESIS OF PROTECTED 3'-AMINONUCLEOSIDE MONOMERS
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
DK3030227T3 (da)	2013-08-07	2020-04-20	Incyte Corp	Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
DK3065828T3 (en) *	2013-11-06	2019-04-15	Mayo Found Medical Education & Res	METHODS AND MATERIALS FOR TREATING HEMATOLOGICAL MALIGNITIES
US10745687B2 (en) *	2015-04-23	2020-08-18	Geron Corporation	Methods of polynucleotide preparation using multivalent cation salt compositions
EP3318276A1 (fr) *	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
WO2019023667A1 (fr)	2017-07-28	2019-01-31	Janssen Biotech, Inc.	Procédés de traitement du syndrome myélodysplasique
IL319432A (en)	2018-04-30	2025-05-01	Kartos Therapeutics Inc	Methods of treating cancer
MX2020012503A (es)	2018-05-25	2021-08-11	Kartos Therapeutics Inc	Métodos de tratamiento de neoplasias mieloproliferativas.
WO2020028261A1 (fr) *	2018-07-31	2020-02-06	Geron Corporation	Méthodes d'identification de patients susceptibles de bénéficier d'un traitement à l'aide d'un inhibiteur de télomérase
JP7650798B2 (ja)	2018-11-29	2025-03-25	ジェロン・コーポレーション	骨髄異形成症候群を治療する方法
EP4054594A4 (fr)	2019-11-04	2023-12-13	Geron Corporation	Utilisation d'un inhibiteur de janus kinase et d'un inhibiteur de télomérase pour le traitement de néoplasmes myéloprolifératifs
JP2021157248A (ja) *	2020-03-25	2021-10-07	パイオニア株式会社	状況出力装置
AU2021309963A1 (en) *	2020-07-17	2023-02-02	Geron Corporation	Subcutaneous telomerase inhibitor compositions and methods for using same
US20240108734A1 (en) *	2021-01-22	2024-04-04	The Regents Of The University Of California	Methods for treating and ameliorating cancer
WO2024259369A1 (fr) *	2023-06-14	2024-12-19	Rarecells Inc.	Compositions ciblant des cellules géantes dans des troubles sanguins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
CA2274586A1 (fr)	1996-12-20	1998-07-02	Geron Corporation	Procedes de detection et d'inhibition de la telomerase dans l'arn
US6331399B1 (en)	2000-05-16	2001-12-18	Isis Pharmaceuticals, Inc.	Antisense inhibition of tert expression
CA2515000A1 (fr) *	2003-01-31	2004-08-19	Jessie L.-S. Au	Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase
CN1244592C (zh) *	2003-07-11	2006-03-08	暨南大学	抑制白血病细胞端粒酶活性的反义核酸及其应用
ES2662196T3 (es)	2003-09-09	2018-04-05	Geron Corporation	Oligonucleótidos modificados para la inhibición de la telomerasa
US20050282893A1 (en) *	2004-01-30	2005-12-22	Au Jessie L	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
DK1778711T3 (en)	2004-07-02	2017-10-02	Geron Corp	SYNTHESIS OF PROTECTED 3'-AMINONUCLEOSIDE MONOMERS
FR2877013A1 (fr)	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en)	2005-01-21	2006-07-27	Bahou Wadie F	Methods of diagnosing essential thrombocythemia
US7998938B2 (en)	2005-04-15	2011-08-16	Geron Corporation	Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (fr) *	2005-04-15	2006-10-26	Geron Corporation	Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
US20070224598A1 (en)	2006-03-15	2007-09-27	The Methodist Hospital Research Institute	System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en)	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
EP4538376A2 (fr)	2006-10-30	2025-04-16	Geron Corporation	Inhibiteur de télomérase combiné et gemcitabine pour le traitement du cancer
CN101220044B (zh) *	2008-01-21	2010-06-02	中国药科大学	端粒酶抑制剂及其制备方法和用途

2013
- 2013-11-15 SM SM20200328T patent/SMT202000328T1/it unknown
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 PH PH1/2019/501008A patent/PH12019501008A1/en unknown
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
- 2013-11-15 MX MX2015007169A patent/MX372753B/es active IP Right Grant
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 SI SI201332080T patent/SI3646876T1/sl unknown
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 IL IL280144A patent/IL280144B2/en unknown
- 2013-11-15 HR HRP20240624TT patent/HRP20240624T1/hr unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/fr not_active Ceased
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 PL PL19187756.2T patent/PL3646876T3/pl unknown
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
- 2013-11-15 IL IL317233A patent/IL317233A/en unknown
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active Active
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
- 2013-11-15 HK HK15111700.1A patent/HK1210940A1/xx unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Ceased
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active Active
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/fr active Pending
- 2013-11-15 KR KR1020257024576A patent/KR20250114449A/ko active Pending
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
- 2013-11-15 SM SM20190567T patent/SMT201900567T1/it unknown
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/fr active Active
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/fr unknown
- 2013-11-15 PT PT191877562T patent/PT3646876T/pt unknown
- 2013-11-15 ES ES19187756T patent/ES2982897T3/es active Active
- 2013-11-15 MY MYPI2020000946A patent/MY200076A/en unknown
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/fr active Active
- 2013-11-15 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/fr active Active
- 2013-11-15 CA CA2892907A patent/CA2892907C/fr active Active
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 HU HUE19187756A patent/HUE066402T2/hu unknown
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 UA UAA202100419A patent/UA128370C2/uk unknown
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282A1/en unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
2019
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142C1/en active Active
2021
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja not_active Withdrawn
- 2022-11-11 ZA ZA2022/12327A patent/ZA202212327B/en unknown
2024
- 2024-05-13 AU AU2024203138A patent/AU2024203138A1/en active Pending
2025
- 2025-05-05 NL NL301326C patent/NL301326I2/nl unknown
- 2025-05-06 LT LTPA2025517C patent/LTPA2025517I1/lt unknown
- 2025-05-07 FI FIC20250019C patent/FIC20250019I1/fi unknown
- 2025-05-07 FR FR25C1016C patent/FR25C1016I1/fr active Active
- 2025-05-07 HU HUS2500019C patent/HUS2500019I1/hu unknown
- 2025-05-12 JP JP2025080100A patent/JP2025109842A/ja active Pending

Also Published As

Publication number	Publication date
EP2928477A4 (fr)	2016-09-21
CA2892907C (fr)	2023-03-21
PH12015501282B1 (en)	2015-08-24
ES2744790T3 (es)	2020-02-26
IL280144B2 (en)	2025-05-01
EP2928477A1 (fr)	2015-10-14
SG11201504383TA (en)	2015-07-30
SG10201802926XA (en)	2018-05-30
LT2928477T (lt)	2019-10-10
AU2024203138A1 (en)	2024-07-25
ES2789176T3 (es)	2020-10-26
LT3456333T (lt)	2020-06-25
NZ748134A (en)	2020-10-30
PT3456333T (pt)	2020-06-01
CN111617252A (zh)	2020-09-04
IL280144B1 (en)	2025-01-01
HRP20200993T1 (hr)	2020-11-27
HUE045098T2 (hu)	2019-12-30
EP3456333B8 (fr)	2020-05-13
IL280144A (en)	2021-03-01
JP2022050537A (ja)	2022-03-30
HK1212226A1 (en)	2016-06-10
AU2013356533B2 (en)	2018-09-27
JP2016504307A (ja)	2016-02-12
KR20230028590A (ko)	2023-02-28
HUE049858T2 (hu)	2020-11-30
JP2018035196A (ja)	2018-03-08
IL239266B (en)	2019-11-28
MX2022015437A (es)	2023-01-11
PL2928477T3 (pl)	2020-03-31
UA126015C2 (uk)	2022-08-03
CN104936602B (zh)	2020-07-17
HUE066402T2 (hu)	2024-07-28
EP3456333B1 (fr)	2020-04-01
KR102294819B1 (ko)	2021-09-01
RS60401B1 (sr)	2020-07-31
HUS2500019I1 (hu)	2025-05-28
JP2022179684A (ja)	2022-12-02
CN104936602A (zh)	2015-09-23
FI3646876T3 (fi)	2024-05-14
PT3646876T (pt)	2024-05-15
NZ708920A (en)	2020-08-28
FIC20250019I1 (fi)	2025-05-07
CL2015001530A1 (es)	2016-03-28
ZA202212327B (en)	2025-03-26
PL3456333T3 (pl)	2020-09-21
RS59363B1 (sr)	2019-11-29
MA45504B1 (fr)	2021-10-29
IL239266A0 (en)	2015-07-30
KR102662590B1 (ko)	2024-05-03
PH12015501282A1 (en)	2015-08-24
JP6433911B2 (ja)	2018-12-05
CY1123206T1 (el)	2021-10-29
KR20150091130A (ko)	2015-08-07
FR25C1016I1 (fr)	2025-06-20
LTPA2025517I1 (fr)	2025-05-26
ZA201504124B (en)	2017-05-31
PT2928477T (pt)	2019-10-25
ME03538B (fr)	2020-07-20
KR20210107906A (ko)	2021-09-01
UA128370C2 (uk)	2024-06-26
SI3456333T1 (sl)	2020-10-30
SI3646876T1 (sl)	2024-07-31
AU2020267142B2 (en)	2024-05-16
HRP20240624T1 (hr)	2024-08-02
WO2014088785A1 (fr)	2014-06-12
MA38193A1 (fr)	2017-12-29
CL2017002156A1 (es)	2018-05-04
UA117116C2 (uk)	2018-06-25
AP2015008504A0 (en)	2015-06-30
SMT201900567T1 (it)	2019-11-13
SMT202000328T1 (it)	2020-07-08
EP3456333A1 (fr)	2019-03-20
PL3646876T3 (pl)	2024-07-22
MX2020003276A (es)	2020-07-20
DK2928477T3 (da)	2019-10-07
EP3646876A1 (fr)	2020-05-06
AU2013356533A1 (en)	2014-06-12
SG10202103341SA (en)	2021-05-28
BR112015013260A2 (pt)	2018-02-06
JP6998191B2 (ja)	2022-02-04
JP2025109842A (ja)	2025-07-25
MX372753B (es)	2020-06-26
MY200076A (en)	2023-12-06
CA3188494A1 (fr)	2014-06-12
EP2928477B1 (fr)	2019-07-24
NL301326I2 (nl)	2025-07-31
ZA202108991B (en)	2023-05-31
CA2892907A1 (fr)	2014-06-12
JP7288098B2 (ja)	2023-06-06
AU2020267142C1 (en)	2024-08-08
AU2020267142A1 (en)	2020-12-03
DK3646876T3 (da)	2024-05-06
WO2014088785A8 (fr)	2015-07-16
MA38193B1 (fr)	2018-12-31
MY180634A (en)	2020-12-03
LT3646876T (lt)	2024-05-10
MX2015007169A (es)	2016-03-31
MA45504A1 (fr)	2020-05-29
HRP20191784T1 (hr)	2019-12-27
EA201590878A1 (ru)	2016-04-29
HK1210940A1 (zh)	2016-05-13
SI2928477T1 (sl)	2019-11-29
PH12019501008A1 (en)	2022-11-14
DK3456333T3 (da)	2020-05-18
EA032973B1 (ru)	2019-08-30
CY1122169T1 (el)	2020-11-25
IL317233A (en)	2025-01-01
AU2018282364A1 (en)	2019-05-23
ES2982897T3 (es)	2024-10-18
EP3646876B1 (fr)	2024-02-14
JP2020041001A (ja)	2020-03-19
KR20250114449A (ko)	2025-07-29

Publication	Publication Date	Title
ZA202212327B (en)	2025-03-26	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
MY185016A (en)	2021-04-30	Progenitor cells of mesodermal lineage
SG178991A1 (en)	2012-04-27	Anti-gitr antibodies
TWD169011S (zh)	2015-07-11	自動點唱機之部分（三）
MX366804B (es)	2019-07-25	Translocaciones de la r-espondina y sus metodos de uso.
MY173726A (en)	2020-02-18	Synbiotics combination for brain improvement
MY158992A (en)	2016-11-30	Forms of rifaximin and uses thereof
MX2019007890A (es)	2020-01-20	Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
EP2558124A4 (fr)	2013-07-24	Compositions de polysaccharide et procédés d'utilisation pour le traitement et la prévention de troubles associés à la mobilisation de cellules progénitrices
MX352927B (es)	2017-12-14	Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
TW201611843A (en)	2016-04-01	Methods of treatment with arginine deiminase
MX2014010940A (es)	2015-04-13	El uso de antitrombina en el tratamiento de preeclampsia.
EA201490562A1 (ru)	2014-08-29	Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
WO2012135818A3 (fr)	2013-01-17	Diagnostics du cancer, agents thérapeutiques et découverte de médicaments associée à la macropinocytose
EA201990799A1 (ru)	2019-09-30	Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм
WO2015060736A3 (fr)	2015-07-30	Utilisation d'agonistes de l'egfr et de l'hgfr en tant que médicaments anticancéreux agissant sur des cellules tumorales présentant un certain phénotype
MA54889A1 (fr)	2022-10-31	Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
이선우	2012	Financial Conditions of People with Disabilities
Xin	2012	The Current Situation and Prospect of Developing School Law of Education in Our Country
AU339611S (en)	2011-11-24	Multifunctional seating
UA112059C2 (uk)	2016-07-25	Комбінована терапія із кріохірургією і іміквімодом для лікування актинічного кератозу (варіанти)
UA70205U (ru)	2012-05-25	Применение растительного препарата трипсидан в качестве лекарственного средства для комплексного лечения постинфекционного астенического синдрома и высокой тревожности у детей школьного возраста в условиях организованных коллективов
AU342740S (en)	2012-05-28	Outdoor dining chair